5 Key Takeaways

• 1

  Duloxetine 120 mg produced more quality-adjusted life-years (QALYs) than amitriptyline in patients with moderate to severe fibromyalgia.

• 2

  The decision analytical model used a Markov cohort state transition approach to estimate costs and QALYs for four fibromyalgia treatments.

• 3

  Duloxetine 120 mg had an incremental cost-effectiveness ratio of $1,536 per QALY compared to amitriptyline, with a net monetary benefit of $40,075.

• 4

  Sensitivity analyses indicated that duloxetine 120 mg had the highest probability of being cost-effective, though uncertainty remained in model parameters.

• 5

  The study emphasizes the importance of considering societal costs in treatment decisions for fibromyalgia, highlighting duloxetine's economic value.